放射性示踪未来:非FDG放射性示踪剂核医学
本文综述非FDG放射性示踪剂在PET/CT中的应用,指出FDG因炎症非特异性摄取及某些肿瘤亚型敏感性有限而催生新型示踪剂。68Ga-DOTA肽、18F-氟环丁氨酸、68Ga-PSMA、11C-胆碱和18F-FDOPA在神经内分泌肿瘤、前列腺癌、胶质瘤和帕金森综合征中展现效用,可提升病灶检测、分期再分期准确性并支持诊疗一体化策略。
要点
- 非FDG示踪剂可弥补FDG在炎症非特异性摄取及部分肿瘤亚型敏感性有限方面的不足。
- 68Ga-DOTA肽、18F-氟环丁氨酸、68Ga-PSMA、11C-胆碱、18F-FDOPA用于神经内分泌肿瘤、前列腺癌、胶质瘤和帕金森综合征。
- 临床应用需理解示踪剂药代动力学、靶点特异性及优化显像方案。
核心结论
- 非FDG PET/CT有望成为精准肿瘤学和跨学科靶向分子影像不可或缺的工具。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 68Ga-DOTA肽、18F-氟环丁氨酸、68Ga-PSMA、11C-胆碱和18F-FDOPA在神经内分泌肿瘤、前列腺癌、胶质瘤和帕金森综合征中已显示效用。
- 非FDG示踪剂的应用可增强疾病检测、提高分期和再分期准确性并支持诊疗一体化策略。
- 非FDG示踪剂具有多样生物学靶点,能更精确地表征组织生理和病理。
关键数值与推荐
- 非FDG PET示踪剂临床整合需细致理解其药代动力学、靶点特异性和最佳显像方案。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Positron Emission Tomography/Computed Tomography (PET/CT) is an advanced hybrid imaging modality that synergistically combines metabolic and anatomical data, revolutionizing diagnostic accuracy and therapeutic monitoring in various pathologies. While 18F-fluorodeoxyglucose (FDG) remains the cornerstone radiotracer for many oncologic and nononcologic applications, its limitations-such as nonspecific uptake in inflammation and limited sensitivity in certain tumor subtypes-have catalyzed the development and clinical adoption of non-FDG radiotracers. These novel agents exhibit diverse biological targets, enabling more precise characterization of tissue physiology and pathology. Among them, radiotracers such as 68Ga-DOTA Peptides, 18F-fluciclovine, 68Ga-PSMA, 11C-choline, and 18F-FDOPA have demonstrated utility in neuroendocrine tumors, prostate cancer, gliomas, and parkinsonian syndromes. Their application enhances disease detection, improves staging and restaging accuracy, and supports theranostic strategies. The integration of non-FDG PET tracers in clinical practice requires nuanced understanding of their pharmacokinetics, target specificity, and optimal imaging protocols. Furthermore, these tracers open avenues for personalized medicine, allowing for biomarker-guided management. As evidence continues to evolve, non-FDG PET/CT is poised to become indispensable in precision oncology and targeted molecular imaging across multiple disciplines.
引用
- Fuso GA, Bianciardi G, Mei R, et al. Radiotracing the Future: Non-FDG Radiotracers Nuclear Medicine. Semin Nucl Med. 2025. PMID: 40675900. doi:10.1053/j.semnuclmed.2025.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。